Viral Vectors and Plasmid DNA Manufacturing Market Forecast Presenting Long-Term Industry Outlook
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Growth In Market Value Is Expected For The Viral Vectors And Plasmid DNA Manufacturing Market Between 2026 And 2030?
The viral vectors and plasmid dna manufacturing market has seen substantial growth recently. It is projected to expand from $7.11 billion in 2025 to $8.79 billion in 2026, achieving a compound annual growth rate (CAGR) of 23.7%. This past growth can be ascribed to an increase in gene therapy research programs, the proliferation of vaccine development initiatives, enhanced academic and clinical research funding, the early stages of cell therapy commercialization, and developments in molecular biology techniques.
The viral vectors and plasmid dna manufacturing market is anticipated to experience substantial growth in the coming years. It is projected to expand to $20.36 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 23.4%. This projected growth throughout the forecast period stems from factors such as increasing approvals for gene and cell therapies, a rising need for commercial-scale production, the expansion of CMO partnerships, a greater emphasis on treatments for rare diseases, and continuous advancements in vector design and production efficiency. Noteworthy trends during this period include the increased deployment of scalable viral vector manufacturing platforms, a growing adoption of single-use bioprocessing systems, an escalating demand for high-purity plasmid dna, an expansion in contract manufacturing capacity, and an enhanced focus on regulatory-compliant production.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20690&type=smp
Which Key Drivers Are Affecting The Viral Vectors And Plasmid DNA Manufacturing Market Development?
The increasing number of gene therapies is anticipated to propel the growth of the viral vectors and plasmid DNA manufacturing market. Gene therapy involves introducing, removing, or altering genetic material within a person’s cells to treat or prevent disease, and its advancement is crucial due to growing investment in biotechnology research and development, coupled with an enhanced understanding of genetic and cellular mechanisms. Viral vectors and plasmid DNA manufacturing are instrumental in facilitating the delivery of therapeutic genes into patients’ cells, enabling the treatment of genetic disorders at the molecular level. For example, according to the American Society of Gene & Cell Therapy, a US-based non-profit medical and scientific organization, the number of gene therapies in Phase III clinical trials expanded by 10% in Q3 2023, marking the first quarterly increase since Q3 2022. Therefore, the expanding pipeline of gene therapies is a key driver for the viral vectors and plasmid DNA manufacturing market.
How Is The Viral Vectors And Plasmid DNA Manufacturing Market Organized By Segment Classification?
The viral vectors and plasmid dna manufacturing market covered in this report is segmented –
1) By Product Type: Plasmid Deoxyribonucleic Acid (DNA), Viral Vector, Non-Viral Vector
2) By Scale Of Operation: Preclinical, Clinical, Commercial
3) By Therapeutic Area: Oncological Disorders, Rare Diseases, Neurological Disorders, Sensory Disorders, Metabolic Disorders, Musculoskeletal Disorders, Blood Disorders, Immunological Disorders, Other Disorders
4) By Application Area: Gene Therapies, Cell Therapies, Vaccines
5) By Type Of Manufacturer: In-house Manufacturers, Contract Manufacturing Organizations
Subsegments:
1) By Plasmid Deoxyribonucleic Acid (DNA): Linear Plasmid DNA, Circular Plasmid DNA, High-Copy Plasmid DNA, Low-Copy Plasmid DNA
2) By Viral Vector: Adenoviral Vectors, Lentiviral Vectors, Adeno-Associated Viral Vectors (AAV), Retroviral Vectors
3) By Non-Viral Vector: Liposome-Based Vectors, Polymer-Based Vectors, Nanoparticle-Based Vectors, Electroporation-Based Vectors
What Trends Are Transforming The Viral Vectors And Plasmid DNA Manufacturing Market?
Leading companies in the viral vectors and plasmid DNA manufacturing market are concentrating on strategic alliances to broaden their production capabilities, improve technological expertise, and speed up the global progression and market entry of gene therapies. Such joint ventures allow companies to share resources and infrastructure, thereby increasing overall production capacity to fulfill the expanding demand for gene therapies. For example, in June 2024, Charles River Laboratories International Inc., a US-based preclinical and clinical contract research organization, and Captain T Cell, a spinoff from the renowned Max Delbrück Center in Berlin, Germany, initiated a program agreement for plasmid DNA and retrovirus vector production. This partnership provides Captain T Cell with access to established contract development and manufacturing (CDMO) capabilities and advisory services. Additionally, its objective is to accelerate the path from preclinical research to clinical trials for an innovative TCR-T cell therapy aimed at solid tumors.
Who Are The Industry Participants Involved In The Viral Vectors And Plasmid DNA Manufacturing Market?
Major companies operating in the viral vectors and plasmid dna manufacturing market are Merck KGaA, Thermo Fisher Scientific Inc., Lonza Group AG, Catalent Inc., Revvity Inc., Wuxi Biologics Inc., FUJIFILM Diosynth Biotechnologies, Miltenyi Biotec GmbH, Aldevron LLC, Takara Bio Inc., Poseida Therapeutics Inc., RegenxBio Inc., Cobra Biologics, Finvector Vision Therapies Limited, Batavia Biosciences B.V., uniQure N.V., Addgene Inc., BioNTech IMFS GmbH, Creative Biogene Inc., Genezen Laboratories Inc., Virovek Incorporation, Waisman Biomanufacturing, Axplora GmbH
Get The Full Viral Vectors And Plasmid DNA Manufacturing Market Report:
Which Region Leads The Viral Vectors And Plasmid DNA Manufacturing Market In Overall Market Size?
North America was the largest region in the viral vectors and plasmid DNA manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vectors and plasmid dna manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Viral Vectors And Plasmid DNA Manufacturing Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Viral Vectors And Plasmid DNA Manufacturing Market 2026, By The Business Research Company
Bacterial And Plasmid Vector Market Report 2026
https://www.thebusinessresearchcompany.com/report/bacterial-and-plasmid-vector-global-market-report
Prenatal Dna Sequencing Market Report
https://www.thebusinessresearchcompany.com/report/prenatal-dna-sequencing-global-market-report
Explosive Ordnance Disposal Equipment Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
